Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLSI Greenwich LifeSciences	$9.21 +0.1%	$9.63	$8.06 ▼ $18.75	$123.12M	1.69	46,610 shs	14,445 shs
HURA TuHURA Biosciences	$2.55 +3.5%	$3.59	$1.80 ▼ $7.93	$110.73M	0.23	233,325 shs	32,188 shs
RANI Rani Therapeutics	$0.51 -2.3%	$0.85	$0.46 ▼ $4.37	$29.49M	0.25	699,287 shs	109,880 shs
TARA Protara Therapeutics	$3.16 +0.6%	$3.49	$1.60 ▼ $10.48	$121.92M	1.34	330,072 shs	57,522 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLSI Greenwich LifeSciences	0.00%	-4.76%	-5.54%	-24.65%	-37.67%
HURA TuHURA Biosciences	0.00%	-12.46%	-37.24%	+1.65%	+245,999,900.00%
RANI Rani Therapeutics	0.00%	-6.20%	-18.00%	-65.89%	-86.97%
TARA Protara Therapeutics	0.00%	-5.99%	-1.57%	-28.96%	+22.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GLSI Greenwich LifeSciences	2.2356 of 5 stars	3.5	1.0	0.0	0.0	2.7	3.3	0.0
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	2.1061 of 5 stars	3.5	1.0	0.0	0.0	2.7	1.7	0.6
TARA Protara Therapeutics	2.4523 of 5 stars	3.6	2.0	0.0	0.0	3.5	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	319.81% Upside
HURA TuHURA Biosciences	3.25	Buy	$12.67	390.01% Upside
RANI Rani Therapeutics	3.00	Buy	$7.33	1,323.95% Upside
TARA Protara Therapeutics	3.14	Buy	$20.50	549.76% Upside

Current Analyst Ratings Breakdown

Latest RANI, GLSI, TARA, and HURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	TARA Protara Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$21.00
5/16/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
5/16/2025	RANI Rani Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$14.00 ➝ $4.00
4/28/2025	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/21/2025	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $39.00
4/16/2025	TARA Protara Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$12.00
4/3/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
4/3/2025	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.52 per share	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	($4.11) per share	N/A
RANI Rani Therapeutics	$1.20M	24.67	N/A	N/A	$0.51 per share	1.01
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$6.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLSI Greenwich LifeSciences	-$8.89M	-$1.26	N/A	N/A	N/A	N/A	-185.12%	-164.27%	8/12/2025 (Estimated)
HURA TuHURA Biosciences	-$8.32M	N/A	0.00	∞	N/A	N/A	N/A	-152.88%	N/A
RANI Rani Therapeutics	-$33.97M	-$0.99	N/A	N/A	N/A	N/A	-219.64%	-56.71%	8/5/2025 (Estimated)
TARA Protara Therapeutics	-$40.42M	-$1.72	N/A	N/A	N/A	N/A	-55.96%	-49.06%	8/5/2025 (Estimated)

Latest RANI, GLSI, TARA, and HURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/15/2025	Q1 2025	HURA TuHURA Biosciences	-$0.13	-$0.15	-$0.02	-$0.15	N/A	N/A
5/13/2025	Q1 2025	RANI Rani Therapeutics	-$0.22	-$0.22	N/A	-$0.22	N/A	$0.20 million
5/8/2025	Q1 2025	TARA Protara Therapeutics	-$0.47	-$0.29	+$0.18	-$0.29	N/A	N/A
4/15/2025	Q4 2024	GLSI Greenwich LifeSciences	-$0.21	-$0.61	-$0.40	-$0.61	N/A	N/A
3/31/2025	Q4 2024	RANI Rani Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	$1.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLSI Greenwich LifeSciences	N/A	6.91	6.91
HURA TuHURA Biosciences	N/A	1.54	1.54
RANI Rani Therapeutics	2.34	1.60	1.60
TARA Protara Therapeutics	N/A	9.85	9.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLSI Greenwich LifeSciences	4.16%
HURA TuHURA Biosciences	0.62%
RANI Rani Therapeutics	30.19%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
GLSI Greenwich LifeSciences	51.67%
HURA TuHURA Biosciences	0.20%
RANI Rani Therapeutics	50.42%
TARA Protara Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.35 million	Not Optionable
HURA TuHURA Biosciences	N/A	43.68 million	42.20 million	N/A
RANI Rani Therapeutics	110	57.48 million	26.75 million	Optionable
TARA Protara Therapeutics	30	38.58 million	18.05 million	Optionable

RANI, GLSI, TARA, and HURA Headlines

Recent News About These Companies

Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025

June 14 at 11:22 AM | seekingalpha.com

Two Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)

June 14 at 3:12 AM | marketbeat.com

Cantor Fitzgerald Forecasts TARA FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Analysts Set Expectations for TARA FY2026 Earnings

June 10, 2025 | marketbeat.com

Chutes & Ladders—Protara gears up for next steps with commercial pro

June 7, 2025 | fiercebiotech.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DE

June 7, 2025 | marketbeat.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by Analysts

June 5, 2025 | marketbeat.com

The Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and more

June 4, 2025 | mmm-online.com

Protara Therapeutics names new Chief Commercial Officer

June 4, 2025 | investing.com

Millennium Management LLC Purchases 357,051 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

June 3, 2025 | marketbeat.com

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

June 2, 2025 | globenewswire.com

Toronto Dominion Bank Acquires New Stake in Protara Therapeutics, Inc. (NASDAQ:TARA)

May 30, 2025 | marketbeat.com

Protara Therapeutics (NASDAQ:TARA) Earns Buy Rating from Analysts at Jones Trading

May 24, 2025 | marketbeat.com

BNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA)

May 24, 2025 | marketbeat.com

Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation

May 23, 2025 | msn.com

Toronto Dominion Bank Takes Position in Protara Therapeutics, Inc. (NASDAQ:TARA)

May 23, 2025 | marketbeat.com

Richard Levy Spends US$64k On Protara Therapeutics Stock

May 22, 2025 | finance.yahoo.com

Velan Capital Investment Management LP Buys 1,005,000 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

May 21, 2025 | marketbeat.com

Janus Henderson Group PLC Invests $11.94 Million in Protara Therapeutics, Inc. (NASDAQ:TARA)

May 19, 2025 | marketbeat.com

With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing

May 16, 2025 | finance.yahoo.com

Protara Therapeutics to Participate in Upcoming Investor Conferences

May 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup
By Gabriel Osorio-Mazilli | June 16, 2025
View Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup

RANI, GLSI, TARA, and HURA Company Descriptions

Greenwich LifeSciences NASDAQ:GLSI

$9.21 +0.01 (+0.11%)

As of 12:31 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

TuHURA Biosciences NASDAQ:HURA

$2.54 +0.09 (+3.46%)

As of 12:31 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Rani Therapeutics NASDAQ:RANI

$0.51 -0.01 (-2.34%)

As of 12:29 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Protara Therapeutics NASDAQ:TARA

$3.16 +0.02 (+0.64%)

As of 12:31 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time